Dr Lutchman poses the question, 'Have we been down this road before?' Is there really a clinical difference in surfactant preparations? The debate of which surfactant to use in the management of very premature infants with respiratory distress syndrome has been ongoing for two decades. In the United States, the debate began with the Food and Drug Administration's approval of the first synthetic surfactant, Exosurf (colfosceril palmitate), closely followed by approval of the animal-derived surfactant, Survanta (beractant). The debate continued with the subsequent approval of more rapidly acting animal-derived surfactants, Infasurf (calfactant) and Curosurf (poractant), with higher concentrations of surfactant phospholipids and surfactant proteins. With preferential purchasing, clinical neonatologists showed their interest in surfactants with a faster onset of action and smaller volume of administration. Slower acting synthetic surfactant, Exosurf, is no longer marketed in the United States. Our recent studies of very premature, mechanically ventilated infants with respiratory distress syndrome 1,2 continue to incrementally evaluate differences in available surfactant preparations. Although we have not shown a difference in mortality with our small sample size, it is clear that poractant alfa has a more rapid onset of action compared with beractant. 3 Poractant alfa, with a larger initial dose (200 mg kg -1 ) compared with beractant (100 mg kg -1 ), made possible by a higher concentration of phospholipid in poractant alfa, is associated with a longer dose-related half-life, giving poractant alfa an additional longer duration of action. 4 Smaller volumes of administration may also reduce the hypercarbia and acute increase in cerebral blood flow, in these very fragile infants. 5 The increased clinical efficacy of multiple doses of poractant alfa (200 mg kg -1 initial dose) was documented in a large European trial. 6 In addition, our preliminary data suggest that improved pulmonary function in the poractant-treated very premature infants with respiratory distress syndrome may reduce the number with clinically significant patent ductus arteriosus. 2 We agree with Dr Lutchman that the surfactant story is far from complete and that ideally a comprehensive series of definitive, randomized control trials of available surfactants, with appropriate power for subgroup analysis, be funded and conducted to assess relative efficacy of surfactant preparations and dosing on preterm infant morbidity and mortality. 7 Unfortunately, these studies are challenging to design, expensive to conduct and the question of how to fund them persists.
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Although it was not too long ago that Holm and Cummings 3 disputed the notion that it was the type of surfactant that reduced preterm infant mortality, these suggestions still continue (and may still continue to confuse and confound). Furthermore, Fujii et al. 1 suggest significant short-term benefits to the use of the larger initial dose of poractant alfa than beractant in very premature infants with RDS. This study compared the clinical efficacy after a recommended dosing of poractant alfa (200 mg kg À1 initial dose and 100 mg kg À1 subsequent doses every 12 to 24 h) with that after beractant (100 mg kg À1 for the initial dose and subsequent doses every 6 to 12 h) among very premature infants with RDS. Not quite comparing apples with apples, but, interestingly, would early administration of the second surfactant dose of beractant in very premature infants with severe RDS produce similar short-term benefits? Köksal et al. 4 showed that there were no significant differences between the premature infants who were given the second beractant dose 2 h (albeit 'off-label') or 6 h after the first dose. There are just too many variables (and limitations) to consider, and again, the generalizability of these results can be debated. All the studies referenced 1,2,4 warrant the need for further studies to confirm the observations. Therefore, the point is that the only mechanism for benefit premature infants receive from surfactants is an improvement in the function of the lung-lining filmFthese surface-active agents have never been shown to reduce a myriad of non-pulmonary complications in this highly vulnerable infant population. 3 
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